http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CA-2502787-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_046cf1b88ab8f4e639b660d4964f7d94 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8e071d18fea054bf8d1420d483e78ed1 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5513 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-32 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-415 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-55 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K- http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-415 |
| filingDate | 2003-10-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fd11b60f729f86bbd7c55db867599f69 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_97a552de6755792ec5492d43acb08579 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_45633d318efb01cd6f516da230918f5d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f1947f315480c902139f4adbd7e1fd10 |
| publicationDate | 2004-04-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CA-2502787-A1 |
| titleOfInvention | Treating alcohol and or substance abuse by antagonizing .alpha. 2 adrenergic receptors with weak dopamine blocking |
| abstract | Certain atypical antipsychotic medications (particularly clozapine) or combinations of medications are useful to treat alcohol or other substance abuse, particularly in the general (non-schizophrenic) population. Generally stated, one aspect of the invention features a method of treating a patient suffering from alcohol or other substance abuse by administering to the patient medication effective to rectify an abuse-associated dysfunction in t he DA-mediated brain reward circuit. A second aspect of the invention features administering medication that strongly antagonizes .alpha.2 andrenergic receptors and weakly antagonizes dopamine D2 receptors. Preferably, the rati o of .alpha.2 receptor blockade to D2o receptor blockade is similar to that of clozapine. The medication may be a single compound (such as clozapine or risperidone), or it may include two or more compounds which together achieve the specified function. For example, the medication may include a first component which weakly blocks the D2 receptor (such as clozapine, quetiapine or ziprasidone or a low dose of another anti-psychotic that is a more potent D2 blocker) and a5 second component (such as clozapine, risperidone or idazoxan) which strongly blocks .alpha.2 receptors, particularly the .alpha. 2C receptor. Cocktails of the twocomponents are also disclosed. |
| priorityDate | 2002-10-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 67.